Alnylam Pharma Secures $500M Credit Agreement

Alnylam Pharma ( (ALNY) ) has issued an update.

On September 30, 2025, Alnylam Pharmaceuticals entered into a Credit Agreement with Bank of America and other lenders, securing a $500 million revolving line of credit. This agreement, which includes a $150 million letter of credit sublimit, allows Alnylam to use the funds for working capital and general corporate purposes. The credit facility is subject to various financial covenants, including maintaining specific leverage and interest coverage ratios, and is secured by the company’s assets. The maturity date for the credit facility is September 30, 2030, with provisions for early maturity under certain conditions.

The most recent analyst rating on (ALNY) stock is a Buy with a $471.00 price target. To see the full list of analyst forecasts on Alnylam Pharma stock, see the ALNY Stock Forecast page.

Spark’s Take on ALNY Stock

According to Spark, TipRanks’ AI Analyst, ALNY is a Neutral.

Alnylam Pharma’s overall stock score is primarily influenced by its strong earnings call performance, which highlights significant revenue growth and positive future guidance. However, financial performance remains a concern due to high leverage and negative profitability, which are significant risks. Technical analysis indicates strong momentum but warns of potential overbought conditions. Valuation metrics are weak due to negative earnings and lack of dividends.

To see Spark’s full report on ALNY stock, click here.

More about Alnylam Pharma

Alnylam Pharmaceuticals, Inc. operates in the biotechnology industry, focusing on the development of RNA interference (RNAi) therapeutics. The company is dedicated to advancing innovative medicines for the treatment of genetic diseases and other health conditions.

Average Trading Volume: 1,154,318

Technical Sentiment Signal: Buy

Current Market Cap: $60.38B

See more data about ALNY stock on TipRanks’ Stock Analysis page.